Clinical trials: T-cell Acute Lymphoblastic Leukemia/Lymphoma
Leukemia, Lymphoma
Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00005580
- Testing
- bryostatin 1, fludarabine phosphate
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Virginia Commonwealth University
T-Cell Leukemia/Lymphoma, Adult
Novel Therapeutic Approach for Human T-cell Malignancies
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
- Trial name
- NCT06600568
- Testing
- Translation analysis
- Where
- 2 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Leukemia, Lymphoma
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
RATIONALE: Donor lymphocytes that have been exposed to Epstein-Barr virus may be able to help the body kill cancers associated with this virus.
- Trial name
- NCT00002956
- Testing
- allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation.
- Conditions
- Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT04128501
- Testing
- Azacitidine, Venetoclax
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Adult T Cell Leukemia, Adult T Cell Lymphoma
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
This clinical trial will be a multicenter phase II fixed-dose trial in which a minimum of 10 patients with immunophenotypically confirmed ATL with at least 50% of the blasts expressing CD25 as measured by flow cytometry at…
- Trial name
- NCT01378871
- Testing
- IMTOX-25
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Amit Verma
Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
This phase I trial studies the side effects of huJCAR014 in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia.
- Conditions
- Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Trial name
- NCT03103971
- Testing
- Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Myeloid, Acute, B-cell Acute Lymphoblastic Leukemia
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
This clinical trial aims to investigate the safety, optimal dosage, and effectiveness of autologous tumor-specific T cells, known as Hema-NeoTIL0 in treating relapsed/refractory B-ALL/AML.
- Trial name
- NCT06559644
- Testing
- Hema-NeoTIL01
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Acute, Chronic Myelogenous Leukemia (CML)
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Patients with hematologic malignancies will receive myeloablative chemotherapy followed by stem cell rescue with bone marrow or hematopoietic peripheral blood stem cells collected by apheresis from a filgrastim- (G-CSF)-mobilized…
- Conditions
- Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
- Trial name
- NCT01050764
- Testing
- Regulatory T-cells, Conventional T-cells, Melphalan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Everett Meyer
B Cell Leukemia, B Cell Lymphoma
Induced-T Cell Like NK Cells for B Cell Malignancies
Relapsed and refractory B cell malignancies show unfavorable prognosis, especially for adult patients. Now, there is no standard management for these patients.
- Conditions
- B Cell Leukemia, B Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Recurrent
- Trial name
- NCT04747093
- Testing
- CAR-ITNK cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
XK469R in Treating Patients With Refractory Hematologic Cancer
Phase I trial to study the effectiveness of XK469R in treating patients who have refractory hematologic cancer. Drugs used in chemotherapy, such XK469R, work in different ways to stop cancer cells from dividing so they stop…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00095797
- Testing
- R(+)XK469, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Adult B-Cell
CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia
This is a single-arm, open-label, single-center, phase I/II study to determine the safety and efficacy of CD19 CAR-T(ssCART-19) combined with autologous T cells engineered to express CD19, namely CD19+ feeding T cells (FTCs), as…
- Trial name
- NCT03984968
- Testing
- ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Lymphoblastic Leukemia
A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
- Trial name
- NCT07066397
- Testing
- ARM011, Fludarabine, Cyclophosphamide
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- TriArm Therapeutics (Taiwan) Limited
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies
- Trial name
- NCT06277011
- Testing
- Metabolically Armed CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Leukemia, Myelodysplastic Syndromes
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
The goal of this study is to see if there is a benefit to giving chemotherapy and then natural killer (NK) cells. The NK cells must come from a family member who shares half of the patients HLA proteins.
- Trial name
- NCT00526292
- Testing
- natural killer cell therapy, cyclophosphamide, fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukemia ALL
Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia
The study is a monocentric, interventional study that evaluates the efficacy of allogeneic HLA-matched or haploidentical transplantation consisting of an irradiation-based conditioning regimen coupled with donor Treg/Tcon…
- Conditions
- Acute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukemia ALL, High Risk Leukaemia, Leukaemia Relapse
- Trial name
- SHARP (NCT06845592)
- Testing
- total marrow/lymphoid irradiation
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- University Of Perugia
Leukemia, Myelodysplastic Syndromes
Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes
RATIONALE: Giving chemotherapy, such as clofarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Trial name
- NCT00641030
- Testing
- clofarabine, melphalan, gene expression analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
B Cell Leukemia
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
Patients with relapsed leukemia often develop resistance to chemotherapy. For this reason, we are attempting to use a patient's own T cells, which can be genetically modified to expresses a chimeric antigen receptor(CAR).
- Trial name
- NCT01683279
- Testing
- Autologous CD19 CAR+ EGFTt + T cells
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Seattle Children's Hospital
Acute Lymphoblastic Leukemia, Immune System Diseases
Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch
This protocol for compassionate use combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone…
- Conditions
- Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
- Trial name
- NCT03594162
- Testing
- iC9-CAR19 cells, AP1903, Cyclophosphamide
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
B-cell Acute Lymphoblastic Leukemia
Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia
The study is in two parts: a dose escalation then a safety dose expansion. The purpose of the dose escalation part is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escalation part) given as a single…
- Trial name
- CALM (NCT02746952)
- Testing
- UCART19
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 25 people
- Sponsor
- Institut de Recherches Internationales Servier
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.